{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:30:31Z","timestamp":1783013431104,"version":"3.54.6"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003347","name":"Fudan University","doi-asserted-by":"publisher","award":["PX201703"],"award-info":[{"award-number":["PX201703"]}],"id":[{"id":"10.13039\/501100003347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.yexcr.2021.112708","type":"journal-article","created":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T10:44:01Z","timestamp":1624099441000},"page":"112708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells"],"prefix":"10.1016","volume":"405","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-2847","authenticated-orcid":false,"given":"Zhen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2021.112708_bib1","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood.V87.8.3069.bloodjournal8783069","article-title":"Treatment of myelogenous leukemia: current status and investigational options","volume":"87","author":"Kantarjian","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2021.112708_bib2","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood.2019000069","article-title":"Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia","volume":"134","author":"Hijiya","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2021.112708_bib3","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41375-018-0369-5","article-title":"Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR\/ABL-induced leukemia","volume":"33","author":"Kollmann","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.yexcr.2021.112708_bib4","doi-asserted-by":"crossref","first-page":"12167","DOI":"10.1074\/jbc.RA119.008037","article-title":"Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7\/JAK1\/STAT5 pathway","volume":"294","author":"Zhang","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yexcr.2021.112708_bib5","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/jcb.25559","article-title":"Targeting the mTOR pathway in leukemia","volume":"117","author":"Dinner","year":"2016","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.yexcr.2021.112708_bib6","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s12094-017-1751-x","article-title":"Expression differences of genes in the PI3K\/AKT, WNT\/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls","volume":"20","author":"de Cassia Viu Carrara","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.yexcr.2021.112708_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1586\/14737140.2016.1151356","article-title":"Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes","volume":"16","author":"Stagno","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.yexcr.2021.112708_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.scr.2018.01.038","article-title":"Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell potential in the absence of glucose","volume":"28","author":"Bono","year":"2018","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.yexcr.2021.112708_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol. Canc."},{"key":"10.1016\/j.yexcr.2021.112708_bib10","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1056\/NEJMe1700833","article-title":"Imatinib changed everything","volume":"376","author":"Longo","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2021.112708_bib11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.yexcr.2021.112708_bib12","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2021.112708_bib13","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation","volume":"123","author":"Nicolini","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.yexcr.2021.112708_bib14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.yexcr.2021.112708_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246141","article-title":"Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update","volume":"20","author":"Bavaro","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexcr.2021.112708_bib16","first-page":"3193","article-title":"Oxidative stress and BCR-ABL1 transcript levels in chronic myeloid leukemia: an intricate relationship","volume":"70","author":"Pascu","year":"2019","journal-title":"Rev. Chem."},{"key":"10.1016\/j.yexcr.2021.112708_bib17","doi-asserted-by":"crossref","unstructured":"Pascu EG, Gaman MA, Moisa C, Assani AD and G. Am, The involvement of oxidative stress in Chronic Myeloid Leukemia, Rom. Biotechnol. Lett. 25 (2020), 1267-1274.","DOI":"10.25083\/rbl\/25.1\/1267.1274"},{"key":"10.1016\/j.yexcr.2021.112708_bib18","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","article-title":"Chronic myeloid leukemia stem cells","volume":"33","author":"Houshmand","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.yexcr.2021.112708_bib19","first-page":"581","article-title":"Signaling pathways involved in chronic myeloid leukemia pathogenesis: the importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells","volume":"22","author":"Moradi","year":"2019","journal-title":"Iran J. Basic Med. Sci."},{"key":"10.1016\/j.yexcr.2021.112708_bib20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3389\/fonc.2019.00939","article-title":"BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia","volume":"9","author":"Loscocco","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.yexcr.2021.112708_bib21","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.4161\/auto.26448","article-title":"HSPA8\/HSC70 chaperone protein: structure, function, and chemical targeting","volume":"9","author":"Stricher","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.yexcr.2021.112708_bib22","doi-asserted-by":"crossref","first-page":"16049","DOI":"10.1074\/jbc.RA119.007416","article-title":"Molecular identification of HSPA8 as an accessory protein of a hyperpolarization-activated chloride channel from rat pulmonary vein cardiomyocytes","volume":"294","author":"Okamoto","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yexcr.2021.112708_bib23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3390\/cells8080849","article-title":"HSPA8\/HSC70 in immune disorders: a molecular rheostat that adjusts chaperone-mediated autophagy substrates","volume":"8","author":"Bonam","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.yexcr.2021.112708_bib24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2174\/1389201020666190516090744","article-title":"Expression profile of genes associated with the proteins degradation pathways in colorectal adenocarcinoma","volume":"20","author":"Martyna","year":"2019","journal-title":"Curr. Pharmaceut. Biotechnol."},{"key":"10.1016\/j.yexcr.2021.112708_bib25","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/ptr.6064","article-title":"Maslinic acid induces autophagy by down-regulating HSPA8 in pancreatic cancer cells","volume":"32","author":"Tian","year":"2018","journal-title":"Phytother Res."},{"key":"10.1016\/j.yexcr.2021.112708_bib26","article-title":"KEGG-expressed genes and pathways in triple negative breast cancer: protocol for a systematic review and data mining","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.yexcr.2021.112708_bib27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.etap.2011.06.001","article-title":"Differential gene expression profiles of human leukemia cell lines exposed to benzene and its metabolites","volume":"32","author":"Sarma","year":"2011","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.yexcr.2021.112708_bib28","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2141.2008.07221.x","article-title":"BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia","volume":"142","author":"Jose-Eneriz","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.yexcr.2021.112708_bib29","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/genes8070174","article-title":"MYC Modulation around the CDK2\/p27\/SKP2 Axis","volume":"8","author":"Hydbring","year":"2017","journal-title":"Genes"},{"key":"10.1016\/j.yexcr.2021.112708_bib30","doi-asserted-by":"crossref","first-page":"10707","DOI":"10.1002\/jcb.28362","article-title":"Overexpression of Hsc70 promotes proliferation, migration, and invasion of human glioma cells","volume":"120","author":"Sun","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.yexcr.2021.112708_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096785","article-title":"Hsc70 contributes to cancer cell survival by preventing Rab1A degradation under stress conditions","volume":"9","author":"Tanaka","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.yexcr.2021.112708_bib32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s13046-019-1336-3","article-title":"GKN2 promotes oxidative stress-induced gastric cancer cell apoptosis via the Hsc70 pathway","volume":"38","author":"Zhang","year":"2019","journal-title":"J. Exp. Clin. Canc. Res."},{"key":"10.1016\/j.yexcr.2021.112708_bib33","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3390\/cells8101260","article-title":"Chaperone-mediated autophagy and its emerging role in hematological malignancies","volume":"8","author":"Robert","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.yexcr.2021.112708_bib34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/cells9020379","article-title":"Trifolium repens blocks proliferation in chronic myelogenous leukemia via the BCR-ABL\/STAT5 pathway","volume":"9","author":"Sarno","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.yexcr.2021.112708_bib35","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1172\/JCI95182","article-title":"Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K\/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells","volume":"127","author":"Kharas","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.yexcr.2021.112708_bib36","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1002\/cncr.31335","article-title":"Targeting autophagy in cancer","volume":"124","author":"Onorati","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.yexcr.2021.112708_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13046-017-0512-6","article-title":"Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia","volume":"36","author":"Lu","year":"2017","journal-title":"J. Exp. Clin. Canc. Res."},{"key":"10.1016\/j.yexcr.2021.112708_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11912-017-0642-1","article-title":"Treatment-free remission: a new therapeutic goal in chronic myelogenous leukemia","volume":"19","author":"Elsayed","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.yexcr.2021.112708_bib39","first-page":"2094","article-title":"[Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives]","volume":"59","author":"Kumagai","year":"2018","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.yexcr.2021.112708_bib40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11899-020-00560-x","article-title":"Mechanisms of cardiovascular toxicity of BCR-ABL1 tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"15","author":"Gustafson","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.yexcr.2021.112708_bib41","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1021\/acsinfecdis.9b00376","article-title":"Small molecule inhibitor of ATPase activity of HSP70 as a Broad-spectrum inhibitor against flavivirus infections","volume":"6","author":"Yang","year":"2020","journal-title":"ACS Infect. Dis."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482721002408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482721002408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:19:19Z","timestamp":1762147159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482721002408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0014482721002408"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2021.112708","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2021.112708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112708"}}